Jump to navigation Jump to search
|Source||Humanized (from mouse)|
|Chemical and physical data|
|Molar mass||148.3 kg/mol g·mol−1|
Refanezumab (GSK249320) is a monoclonal antibody designed for the recovery of motor function after stroke.
This drug was developed by GlaxoSmithKline.
|This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.|